GSK plc
GLAXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.96 | 0.03 | -0.04 |
| FCF Yield | 4.15% | 2.65% | 1.12% | 2.18% |
| EV / EBITDA | 22.92 | 15.99 | 24.71 | 60.91 |
| Quality | ||||
| ROIC | 5.28% | 4.54% | 4.45% | 1.54% |
| Gross Margin | 73.58% | 72.89% | 74.23% | 68.47% |
| Cash Conversion Ratio | 1.12 | 1.27 | 0.65 | 4.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.75% | 2.54% | 2.73% | -0.57% |
| Free Cash Flow Growth | 77.66% | 109.90% | -41.62% | -8.99% |
| Safety | ||||
| Net Debt / EBITDA | 4.30 | -1.11 | 4.52 | 11.88 |
| Interest Coverage | 15.53 | 10.99 | 13.68 | 4.83 |
| Efficiency | ||||
| Inventory Turnover | 0.37 | 0.36 | 0.32 | 0.45 |
| Cash Conversion Cycle | -297.35 | -281.15 | -340.57 | 144.14 |